Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
Lung Cancer
; 87(1): 85-7, 2015 Jan.
Article
in En
| MEDLINE
| ID: mdl-25466451
ABSTRACT
We present the case of a patient with rapidly accelerated fibrosarcoma gene F (BRAF) mutated adenocarcinoma of the lung, responding to BRAF inhibitor dabrafenib after progressing on vemurafenib followed by docetaxel. The present case illustrates the potential benefit of successful rechallenge with a BRAF inhibitor, a well known phenomenon observed in other oncogenic driven molecular subtypes of non-small cell lung cancer (NSCLC) such as epidermal growth factor receptor mutation. Rechallenge with a BRAF inhibitor in BRAF mutated NSCLC should be considered, particularly in the absence of alternative therpateutic options.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oximes
/
Carcinoma, Bronchogenic
/
Adenocarcinoma
/
Proto-Oncogene Proteins B-raf
/
Imidazoles
/
Lung Neoplasms
/
Mutation
Type of study:
Diagnostic_studies
Limits:
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lung Cancer
Year:
2015
Document type:
Article